January 15, 2010 โ The U.S. Patent Office this week issued a patent for the wireless transmission system used by the CardioBip remote monitor, which generates recordings equivalent in quality with standard 12-lead ECGs.
January 13, 2010 โ The FDA this week granted 510(k) market clearance for the JETSTREAM G3 atherectomy catheter. It features a new distal cutter and enhanced aspiration efficiency over the previous JETSTREAM G2 device.
January 13, 2010 โ The January issue of the Harvard Heart Letter says assessing a patientโs โartery ageโ can help predict the personโs chances for vascular diseases, including heart disease. The article also offers a survey to help judge artery age.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
January 14, 2009 โ Implementing a cardiac imaging benefit management program like those used in the private sector could help the Centers for Medicare and Medicaid Services (CMS) avoid reimbursement cuts that may drive cardiologists and other specialty physicians out of business.
January 13, 2010 โ A study evaluating the effectiveness of the Clir-Path laser atherectomy system met its primary endpoint by reducing the diameter of stenosis. Results from the CELLO (CLiRpath Excimer Laser System to Enlarge Lumen Openings) study were published in the December issue of the Journal of Endovascular Therapy.
January 13, 2010 โ Diagnostic cardiac monitor company Cardiac Science is working to connect its devices with MEDENT's electronic medical record (EMR) system.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
January 13, 2010 โ Transcatheter heart valve development company CardiAQ Valve Technologies (CVT) closed a $6.5 million funding deal to clinically validate its technology and carry the company through initial first-in-man studies.
January 12, 2010 โ In its January issue, Prevention magazine named the Endo-PAT2000 endothelial function testing device one of the top medical breakthroughs of 2009.
January 2, 2010 โ The FDA cleared the Celsius RMT ThermoCool ablation catheter for use with Stereotaxis' magnetic navigation system in the treatment of type 1 atrial flutter.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
January 11, 2010 โ Health Canada, the Canadian equivalent of the U.S. FDA, cleared heart sound analysis software that connects wirelessly to a Bluetooth-enabled electronic stethoscope.
January 11, 2010 โ A hypertension drug using a combination of telmisartan/amlodipine, which requires less-frequent dosing than Novartis's Diovan/Tareg (valsartan), may earn 30 percent patient share according to surveyed U.S. cardiologists. Similarly, in Europe, the agent would earn comparable patient share of 25 percent according to surveyed European cardiologists.
January 11, 2010 โ The first patients were enrolled in the phase 3 clinical trials for a drug designed to lower triglycerides for patients at risk for cardiovascular disease.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
January 8, 2010 โ Transradial angiography leads to reduced patient complications, faster recovery time and decreased hospital costs, according to cardiologists at the University of Illinois at Chicago (UIC) and Jesse Brown VA medical centers. They are among the first in the Chicago area to offer the new approach to heart angiograms and clearing blocked arteries.
January 8, 2010 โ Japanese regulatory officials this week cleared the XIENCE V Everolimus-Eluting Coronary Stent. Abbott said it plans to launch sales in Japan in the coming weeks, immediately following final reimbursement authorization.
January 7, 2010 โ Doctors with Virginia Interventional and Vascular Associates (VIVA) report success in treating acute deep vein thrombosis (DVT) with a procedure called isolated pharmacomechanical thrombolysis (IPMT). The treatment has been used for the past two years to destroy clots much faster than traditional therapies.